- Home
- ASM vs DMRA Comparison
ASM vs DMRA Comparison
Compare ASM & DMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ASM | DMRA |
|---|---|---|
| Founded | 1968 | 2011 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Metal Mining | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.5B |
| IPO Year | 2005 | 2020 |
Fundamental Metrics
Financial Performance| Metric | ASM | DMRA |
|---|---|---|
| Price | $6.45 | $28.41 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 2 |
| Target Price | $8.18 | ★ $43.00 |
| AVG Volume (30 Days) | ★ 4.4M | 304.7K |
| Earning Date | 05-13-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 121.48 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $53.35 | N/A |
| Revenue Next Year | $34.26 | N/A |
| P/E Ratio | $67.93 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.05 | $16.50 |
| 52 Week High | $11.99 | $34.89 |
Technical Indicators
Market Signals| Indicator | ASM | DMRA |
|---|---|---|
| Relative Strength Index (RSI) | 50.60 | 40.75 |
| Support Level | $6.84 | $22.71 |
| Resistance Level | $7.47 | $28.66 |
| Average True Range (ATR) | 0.36 | 1.78 |
| MACD | -0.07 | -0.40 |
| Stochastic Oscillator | 22.45 | 21.13 |
Price Performance
Historical ComparisonAbout ASM Avino Silver & Gold Mines Ltd. (Canada)
Avino Silver & Gold Mines Ltd is a mineral resource company. It is engaged in the exploration, extraction, and processing of silver, gold, and copper and the acquisition, exploration, and advancement of mineral properties. The company generates majority of its revenues through the sale of Copper produced from its mines. Its project portfolio includes Avino; San Gonzalo; Oxide Tailings; Bralorne Gold and others.
About DMRA Damora Therapeutics Inc. Common Stock
Damora Therapeutics Inc is a biotechnology company that aims to fundamentally redefine care for people with hematologic disorders. The group is advancing a new generation of biologics to treat mutant calreticulin-driven myeloproliferative neoplasms, including essential thrombocythemia and myelofibrosis, where there is cruicial medical need for disease-modifying treatments. Its goal is to rapidly bring forward optimized therapies with broad mutation coverage and exceptional convenience to dramatically improve patient outcomes. The group's pipeline products are DMR-001, DMR-002, DMR-003, and GB3226.